BMS signs deal with Medicines Patent Pool for second-line HIV treatment
This article was originally published in Scrip
Executive Summary
The Medicines Patent Pool (MPP) and Bristol-Myers Squibb have signed a licensing agreement to increase access to the HIV medicine, atazanavir (Reyataz), in 110 developing countries. "These countries represent 88.5% of people living with HIV/AIDS in developing countries," said the MPP.